Share: Facebook Twitter LinkedIn
Activity Provided By:

ACHL

Recognizing the Substantial Burden of Alopecia in Pediatric Patients and Building Multidisciplinary Capacity and Competence to Address Unmet Needs

Access Activity

Overview / Abstract:

Hair loss can have a profound psychological impact, especially on adolescents who may face social stigma or have self-esteem issues. Accurate diagnosis and appropriate management in this patient population can improve not only physical symptoms but also mental well-being.

If you’re a clinician who treats alopecia areata (AA) in pediatric patients, take your skills to the next level by accessing ACHL’s AdaptED® platform, which offers a tailored learning experience for busy clinicians, addressing your specific goals and knowledge gaps while providing practical insights and strategies for immediate application in practice. Whether you are an early career clinician or an advanced provider, stay up to date on the latest evidence and evolving practices on diagnosing and treating AA in pediatric patients. Enhance patient care by accessing the ACHL AdaptED® platform today.

Expiration

Mar 19, 2025

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Online, Webinar / Webcast / Video

Credits / Hours

2.0 hours

Accreditation

ACCME, ANCC

Presenters / Authors / Faculty

Carolyn Goh, MD (Faculty)
Consulting Agreements: Radicle Sciences, Sagimet Biosciences
Advisory Board: Pelage Pharmaceuticals
Contributor: BMJ BestPractices
Speakers' Bureau: Pfizer, Inc.

Lacey Kruse (Faculty)
Sources of Funding for Research: Leo Pharma, Sanofi

Diane Hountz, DNP, MS, ANP, RN, CNE (Nurse Planner)
No financial relationships to disclose

Sponsors / Supporters / Grant Providers

Provided by the Academy for Continued Healthcare Learning (ACHL) and Purdue University College of Pharmacy Office of Continuing Education and Professional Development.

Supported by an educational grant from Pfizer, Inc.

Keywords / Search Terms

ACHL AdaptED, personalized learning, Pfizer, alopecia areata (AA), pediatrics, dermatology, emerging therapies, oral Janus kinase (JAK) inhibitors, adolescent patients, immune cells, cytokines, signaling pathways, heterogeneity, inflammatory skin diseases, pathogenesis prospects, therapeutic prospects, disease impact and patient quality of life (QoL), specialty care, pediatric-focused dermatological care Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map